SV
Shraddha Vinayak Dhamankar
About Shraddha Vinayak Dhamankar
Data last updated:
Shraddha Vinayak Dhamankar is a Director at Enem Nostrum Remedies Private Limited (since 2001), Director at Thurs Organics Private Limited (since 2009) and Director at Nli Healthcare (India) Private Limited (since 2019), and holds 6 more current directorships. The companies operate in Pharma, Chemicals and Materials and Information Technology. The 9 current companies with reported revenue have a combined latest revenue of ₹64.52 Cr; the largest is Enem Nostrum Remedies Private Limited at ₹42.33 Cr (FY 2025). Earlier, Shraddha Vinayak Dhamankar was a Director at Vidit Pharma Sciences Private Limited (from 2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 01 Jan 2001 | 2001 | ₹42.33 Cr (FY 2025) | Active | |
| Director | 30 Nov 2009 | 1997 | ₹21.47 Cr (FY 2024) | Active | |
| Director | 15 Feb 2019 | 2019 | ₹58.9 Lakh (FY 2024) | Active | |
| Director | 06 Sep 2004 | 2004 | ₹6.3 Lakh (FY 2025) | Active | |
| Director | 24 Jan 2007 | 2007 | ₹5.5 Lakh (FY 2025) | Active | |
| Director | 14 Dec 2011 | 2011 | ₹35,170 (FY 2023) | Active | |
| Director | 27 Aug 2007 | 2007 | ₹21,450 (FY 2022) | Active | |
| Director | 01 Jan 2020 | 2000 | ₹20,120 (FY 2022) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 21 Jan 2022 | 2022 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Shraddha Vinayak Dhamankar
| Name | DIN | Company | Designation |
|---|---|---|---|
| Anilkumar Shridhar Mulye | 10772965 | Enem Nostrum Remedies Private Limited , Nli Healthcare (India) Private Limited and 6 more | Director |
| Vinayak Atmaram Dhamankar | 02727797 | Thurs Organics Private Limited | Director |
| Kaushik Krishnakant Vyas | 08642670 | Symmetrix Biotech Private Limited | Director |
| Rama Ravikiran Marathe | 05191501 | Symmetrix Biotech Private Limited | Director |
| Yatindra Prashar | 02673472 | Symmetrix Biotech Private Limited | Director |
| Nirmal Vasant Mulye | 01459942 | Bombay Bio-Research Centre Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Shraddha Vinayak Dhamankar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shraddha Vinayak Dhamankar
Shraddha Vinayak Dhamankar currently holds 9 directorships: Enem Nostrum Remedies Private Limited (Director, since 01 Jan 2001, revenue ₹42.33 Cr (FY 2025)); Thurs Organics Private Limited (Director, since 30 Nov 2009, revenue ₹21.47 Cr (FY 2024)); Nli Healthcare (India) Private Limited (Director, since 15 Feb 2019, revenue ₹58.9 Lakh (FY 2024)); Nexgen Healthcare Private Limited (Director, since 06 Sep 2004, revenue ₹6.3 Lakh (FY 2025)); Symmetrix Biotech Private Limited (Director, since 24 Jan 2007, revenue ₹5.5 Lakh (FY 2025)); and 4 more.
Shraddha Vinayak Dhamankar was first appointed on 01 Jan 2001 as Director at Enem Nostrum Remedies Private Limited. The most recent appointment on record is 21 Jan 2022 at Vidit Pharma Sciences Private Limited.
The 9 current companies of Shraddha Vinayak Dhamankar that report revenue have a combined latest revenue of ₹64.52 Cr: Enem Nostrum Remedies Private Limited ₹42.33 Cr (FY 2025); Thurs Organics Private Limited ₹21.47 Cr (FY 2024); Nli Healthcare (India) Private Limited ₹58.9 Lakh (FY 2024); Nexgen Healthcare Private Limited ₹6.3 Lakh (FY 2025); Symmetrix Biotech Private Limited ₹5.5 Lakh (FY 2025); and 4 more.
Shraddha Vinayak Dhamankar held 1 earlier board appointment: Vidit Pharma Sciences Private Limited (Director, from 21 Jan 2022).
The current boards of Shraddha Vinayak Dhamankar's companies include Anilkumar Shridhar Mulye (Enem Nostrum Remedies Private Limited), Vinayak Atmaram Dhamankar (Thurs Organics Private Limited), Kaushik Krishnakant Vyas (Symmetrix Biotech Private Limited), Rama Ravikiran Marathe (Symmetrix Biotech Private Limited), Yatindra Prashar (Symmetrix Biotech Private Limited), Nirmal Vasant Mulye (Bombay Bio-Research Centre Private Limited).